19 May - 9 Jun 2022Warrant exercise

Modus is a clinical biotechnology company that, through the polysaccharide sevuparin, is developing a treatment for sepsis and septic shock – a serious and often fatal condition. Modus treatment is aimed at anyone suffering from sepsis or septic shock, and since there is no treatment available for these serious conditions, a future treatment places itself in a high-priced segment. The company’s primary focus is the upcoming clinical phase Ib-LPS provocation study in sepsis / septic shock and a clinical phase IIa-Proof-of-Concept study in sepsis / septic shock. Mode’s vision is to create an effective treatment for patients with sepsis and septic shock that binds and neutralizes the harmful substances secreted in the blood during hyperinflammation to stabilize the initial bacterial infection.

Read more on the company's website

The offer in summary